Iliana Doycheva1, Kymberly D Watt2, Ghassoub Rifai3, Rachel Abou Mrad3, Rocio Lopez4, Nizar N Zein3, William D Carey3, Naim Alkhouri5,6. 1. Division of Gastroenterology and Hepatology, Medical University, Sofia, Bulgaria. 2. Gastroenterology and Hepatology Department, Mayo Clinic, Rochester, MN, USA. 3. Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA. 4. Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. 5. Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA. alkhoun@ccf.org. 6. Department of Pediatric Gastroenterology and Hepatology, Cleveland Clinic Children's Hospital, 9500 Euclid Avenue, A-111, Cleveland, OH, 44195, USA. alkhoun@ccf.org.
Abstract
BACKGROUND AND AIMS: Chronic liver disease (CLD) starts or becomes established in the adolescent and young adult (AYA) age group. This study aimed to estimate trends in CLD prevalence among US AYAs and to assess factors associated with CLD. METHODS: Cross-sectional data from 14,547 AYAs (population-weighted N = 68,274,386) aged 15-39 years enrolled in the National Health and Nutrition Examination Survey from 1988 to 2012 were used. Nonalcoholic fatty liver disease (NAFLD) was defined as elevated alanine aminotransferase (>19 U/L for females and >30 U/L for males) in subjects with BMI ≥ 25 kg/m2; alcoholic liver disease (ALD) as excessive alcohol use (≥3 drinks/day for men and ≥2 drinks/day for women) and elevated aminotransferases after excluding alternative etiologies. Participants were considered hepatitis C virus (HCV) positive if antibody to HCV and HCV-RNA was positive. RESULTS: There was a sharp increase in the prevalence of CLD from 12.9% in 1988-1994 to 28.5% in 1999-2004 that remained stable after that (27.7%). NAFLD was the most common etiology accounting for 22% of all CLD in the later period. The prevalence of ALD has been steadily increasing throughout the years, while HCV has been decreasing. On multivariate analysis, being overweight/obese, Mexican-American ethnicity, later study period, older age, and male gender, were associated with higher odds of having CLD. CONCLUSION: More than one quarter of US AYAs might be affected by CLD. CLD prevalence in this age group has more than doubled over the past three decades mainly due to rise in NAFLD prevalence.
BACKGROUND AND AIMS: Chronic liver disease (CLD) starts or becomes established in the adolescent and young adult (AYA) age group. This study aimed to estimate trends in CLD prevalence among US AYAs and to assess factors associated with CLD. METHODS: Cross-sectional data from 14,547 AYAs (population-weighted N = 68,274,386) aged 15-39 years enrolled in the National Health and Nutrition Examination Survey from 1988 to 2012 were used. Nonalcoholic fatty liver disease (NAFLD) was defined as elevated alanine aminotransferase (>19 U/L for females and >30 U/L for males) in subjects with BMI ≥ 25 kg/m2; alcoholic liver disease (ALD) as excessive alcohol use (≥3 drinks/day for men and ≥2 drinks/day for women) and elevated aminotransferases after excluding alternative etiologies. Participants were considered hepatitis C virus (HCV) positive if antibody to HCV and HCV-RNA was positive. RESULTS: There was a sharp increase in the prevalence of CLD from 12.9% in 1988-1994 to 28.5% in 1999-2004 that remained stable after that (27.7%). NAFLD was the most common etiology accounting for 22% of all CLD in the later period. The prevalence of ALD has been steadily increasing throughout the years, while HCV has been decreasing. On multivariate analysis, being overweight/obese, Mexican-American ethnicity, later study period, older age, and male gender, were associated with higher odds of having CLD. CONCLUSION: More than one quarter of US AYAs might be affected by CLD. CLD prevalence in this age group has more than doubled over the past three decades mainly due to rise in NAFLD prevalence.
Entities:
Keywords:
Alcoholic liver disease; Hepatitis C; Nonalcoholic fatty liver disease; Obesity; Young population
Authors: Clifford L Johnson; Ryne Paulose-Ram; Cynthia L Ogden; Margaret D Carroll; Deanna Kruszon-Moran; Sylvia M Dohrmann; Lester R Curtin Journal: Vital Health Stat 2 Date: 2013-09
Authors: Anil G Suryaprasad; Jianglan Z White; Fujie Xu; Beth-Ann Eichler; Janet Hamilton; Ami Patel; Shadia Bel Hamdounia; Daniel R Church; Kerri Barton; Chardé Fisher; Kathryn Macomber; Marisa Stanley; Sheila M Guilfoyle; Kristin Sweet; Stephen Liu; Kashif Iqbal; Rania Tohme; Umid Sharapov; Benjamin A Kupronis; John W Ward; Scott D Holmberg Journal: Clin Infect Dis Date: 2014-08-11 Impact factor: 9.079
Authors: Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg Journal: Ann Intern Med Date: 2014-03-04 Impact factor: 25.391
Authors: Gilad Twig; Gal Yaniv; Hagai Levine; Adi Leiba; Nehama Goldberger; Estela Derazne; Dana Ben-Ami Shor; Dorit Tzur; Arnon Afek; Ari Shamiss; Ziona Haklai; Jeremy D Kark Journal: N Engl J Med Date: 2016-04-13 Impact factor: 91.245
Authors: Justin Knox; Melanie Wall; Katie Witkiewitz; Henry R Kranzler; Daniel E Falk; Raye Litten; Karl Mann; Stephanie S O'Malley; Jennifer Scodes; Raymond Anton; Deborah S Hasin Journal: Drug Alcohol Depend Date: 2019-05-29 Impact factor: 4.492
Authors: Justin Knox; Jennifer Scodes; Melanie Wall; Katie Witkiewitz; Henry R Kranzler; Daniel Falk; Raye Litten; Karl Mann; Stephanie S O'Malley; Raymond Anton; Deborah S Hasin Journal: Drug Alcohol Depend Date: 2019-02-14 Impact factor: 4.492
Authors: Galit Weinstein; Shira Zelber-Sagi; Sarah R Preis; Alexa S Beiser; Charles DeCarli; Elizabeth K Speliotes; Claudia L Satizabal; Ramachandran S Vasan; Sudha Seshadri Journal: JAMA Neurol Date: 2018-01-01 Impact factor: 18.302